Speaker Profile
Ph.D., CEO and Co-Founder, Hepta
Biography
Hamed Amini is Co-Founder and CEO of Hepta, an AI-native liquid biopsy company building the diagnostic and data platform for chronic disease, beginning with MASH. Hepta decodes cell-free DNA methylation signals in blood to deliver tissue-level insight without biopsy, powered by LiquidTransformer, a transformer AI architecture purpose-built for liquid biopsy in chronic disease.
Hamed founded Hepta in 2022 after more than a decade at the forefront of genomics and diagnostics. He was a founding team member at GRAIL, where he led work across technology and product development and translational strategy, and played a pivotal role in developing and launching Galleri, GRAIL's flagship multi-cancer early detection test. Earlier, he was a scientist in Illumina's research division, working at the forefront of next-generation sequencing technologies.
He holds a Ph.D. in Biomedical Engineering from UCLA and a B.Sc. in Mechanical Engineering from Sharif University of Technology.
Session Abstract – PMWC 2027 Silicon Valley
Track Chair:
Victor Velculescu, Johns Hopkins
PMWC Award Ceremony
• Rebecca Fitzgerald, University of Cambridge (Luminary)
• Mary-Claire King, University of Washington (Pioneer)
• Nickolas Papadopoulos, Johns Hopkins (Pioneer)
Featured Speakers
• Mary-Claire King, University of Washington
• Rebecca Fitzgerald, University of Cambridge
• Nickolas Papadopoulos, Johns Hopkins
• Victor Velculescu, Johns Hopkins
• Phil Castle, NIH
• Elad Ziv, UCSF
• Ash Alizadeh, Stanford
• Hamed Amini, Hepta
• Becky Taub, Madrigal Pharmaceuticals
• Trevor Pugh, University of Toronto
• Doga Gulhan, Harvard
• Pranav Rajpurkar, Harvard
• Chris Douville, Johns Hopkins
• Sylvia Katina Plevritis, UCSF
In Precision Medicine, Almost All Diseases Are Genetically Rare
A genetics-first keynote framing risk, prevention, and actionability.
The Reckoning
What the first wave of early detection got right and wrong.
The End of One Size Fits All
Risk-stratified screening, high-risk populations, and single-cancer tests.
Treating Disease at the Earliest Stage
Where detection and therapeutic interception begin to converge.
Pre-Cancer Detection & the Liver Disease Frontier
cfDNA and clinical action across the liver-disease-to-cancer continuum.
AI Across Multimodal Signals
Fragmentomics, methylation, imaging, pathology, and integration: hype versus real science.
PMWC Hall of Impact
Previous Speakers Include
Nobel laureates, technology founders, regulators, CEOs and scientific pioneers who have taken the PMWC stage.
